Governance Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:27:02 17/02/2026 GMT			5-day change	1st Jan Change
6.130 ^USD	+0.66%		-17.12%	-30.27%

02-12	Vanda Pharmaceuticals Inc files for mixed shelf offering of up to $200 million - SEC filing	RE
02-12	Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026

Executive Committee: Vanda Pharmaceuticals Inc.

Manager

Positions heldSince

Mihael Polymeropoulos

66 year

Chief Executive Officer	30/04/2003
Founder	31/10/2002
President	30/04/2003

Tim Williams

50 year

General Counsel	12/08/2018
Corporate Secretary	12/08/2018

Kim Wijkstrom

60 year

Sales & Marketing

20/08/2019

Scott Howell

Human Resources Officer

31/07/2019

Kevin Moran

42 year

Director of Finance/CFO	14/03/2020
Investor Relations Contact	30/11/2012
Treasurer	14/03/2020

Composition of the Board of Directors: Vanda Pharmaceuticals Inc.

Director

CommitteesSince

Mihael Polymeropoulos

66 year

Chairman

31/05/2021

Anne Ward

54 year

Audit Committee	05/11/2020
Compensation Committee Chair
Governance Committee Chair	05/11/2020
Nominating Committee Chair	05/11/2020

Tage Honoré

75 year

Compensation Committee	14/03/2023
Governance Committee	14/03/2023
Nominating Committee	14/03/2023

Phaedra Chrousos

46 year

Audit Committee	23/04/2019
Governance Committee Chair
Nominating Committee Chair

Stephen Mitchell

74 year

Governance Committee	13/02/2020
Nominating Committee	13/02/2020

Richard Dugan

84 year

Compensation Committee	30/11/2005
Audit Committee Chair	30/11/2005

Latest Appointments: Vanda Pharmaceuticals Inc.

17/03/23	Vanda Pharmaceuticals Inc. Appoints Dr. Tage Honoré to its Board of Directors	CI
25/04/22	H. Thomas Watkins Not Stands for Reelection of Vanda Pharmaceuticals Inc	CI
08/10/21	Vanda Pharmaceuticals Inc. Announces Resignation of Aranthan “Aj” Jones II as the Corporate Affairs and Communications Officer	CI
22/04/20	Vanda Pharmaceuticals Inc. Announces Resignation of Mihael H. Polymeropoulos as Director	CI
03/03/20	Vanda Pharmaceuticals Inc. Announces Resignation of Gian Piero Reverberi as Senior Vice President and Chief Commercial Officer, Effective as of March 16, 2020	CI
20/02/20	Vanda Pharmaceuticals Inc. Announces Executive Changes, Effective March 15, 2020	CI
19/02/20	Vanda Pharmaceuticals Inc. Announces Board Changes	CI

More news

Former Officers and Directors: Vanda Pharmaceuticals Inc.

Insider

Positions held

SinceUntil

H. Watkins

Director/Board Member	11/09/2006	31/10/2011
Chairman	30/03/2014	-
Independent Dir/Board Member	11/09/2006	15/06/2022

Aranthan Jones

Public Communications Contact	20/08/2019	25/10/2021
General Counsel	20/08/2019	25/10/2021

Gian Reverberi

Corporate Officer/Principal

07/09/2015

15/03/2020

James Kelly

Comptroller/Controller/Auditor	-	12/08/2018
Director of Finance/CFO	14/12/2010	14/03/2020
Investor Relations Contact	12/12/2010	14/03/2020
Corporate Secretary	14/12/2010	12/08/2018
Treasurer	14/12/2010	14/03/2020

Michael Cola

Director/Board Member	17/06/2012	13/02/2020
Independent Dir/Board Member	17/06/2012	13/02/2020

Vin Milano Milano

Director/Board Member	20/04/2010	12/06/2019
Independent Dir/Board Member	14/04/2010	12/06/2019

Ken Bate

Director/Board Member	16/12/2015	12/06/2018
Independent Dir/Board Member	16/12/2015	12/06/2018

Richard L. Gulino

General Counsel	13/09/2015	01/05/2018
Corporate Secretary	13/09/2015	01/05/2018

Howard H. Pien

Director/Board Member	04/06/2007	31/12/2009
Chairman	31/12/2009	31/12/2015
Independent Dir/Board Member	04/06/2007	31/12/2009

Thomas Gibbs

Corporate Officer/Principal	19/04/2015	16/12/2015
Corporate Officer/Principal	28/02/2015	30/11/2015

Steven Galson

Director/Board Member	01/07/2010	17/06/2015
Independent Dir/Board Member	30/06/2010	17/06/2015

Philip Herman

Sales & Marketing

31/12/2012

28/02/2015

Robert Repella

Corporate Officer/Principal

25/10/2011

Joseph A. Sliman

Chief Tech/Sci/R&D Officer

31/08/2012

31/12/2013

Argeris Karabelas

Director/Board Member	14/11/2011	17/01/2012
Chairman	17/11/2009	14/11/2011
Founder	31/12/2001	14/11/2011
Independent Dir/Board Member	15/11/2011	17/01/2012

Stephanie R. Irish

Comptroller/Controller/Auditor	05/08/2010	05/08/2010
Director of Finance/CFO	05/08/2010	05/08/2010
Corporate Secretary	05/08/2010	05/08/2010
Treasurer	05/08/2010	05/08/2010

Brian Halak

Director/Board Member

31/12/2003

20/04/2010

Chip Clark

Founder	31/12/2001	25/03/2010
Corporate Secretary	31/12/2002	25/03/2010

David Ramsay

Director/Board Member

31/12/2003

06/01/2010

Frederick H. Graff

Sales & Marketing

31/12/2007

31/12/2009

Steven Shallcross

Director of Finance/CFO	31/10/2005	08/01/2009
Treasurer	31/10/2005	08/01/2009

Paolo Baroldi

Chief Tech/Sci/R&D Officer	30/06/2006	08/01/2009
Chief Tech/Sci/R&D Officer	16/04/2013	21/03/2017

Todd Horich

Sales & Marketing

31/12/2005

31/12/2008

Albert W. Gianchetti

Corporate Officer/Principal

24/10/2007

30/11/2008

Jan Smilek

Director of Finance/CFO

31/12/2005

31/01/2008

John Joseph Feeney

Chief Tech/Sci/R&D Officer

08/01/2009

Thomas Lyle Copmann

General Counsel

31/03/2005

23/10/2007

James Tananbaum

Director/Board Member

31/12/2003

04/06/2007

Wayne T. Hockmeyer

Director/Board Member

31/12/2003

11/09/2006

Heng Tong Choo

Director/Board Member

Ankit Mahadevia

Corporate Officer/Principal

Curt Wolfgang

General Counsel

Cristina Murphy

Investor Relations Contact	25/10/2011	-
Public Communications Contact	04/07/2010	-

Mark Leschly

Director/Board Member

Ashish Khanna

Corporate Officer/Principal

Christian Lavedan

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	10
Female	2

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	4
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

533

Sector

Biotechnology & Medical Research

Calendar

05-05 - Q1 2026 Earnings Release (Projected)

More about the company